These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25670403)

  • 1. Vaccine evaluation: lessons from a meningococcal B vaccine.
    Sarfatti A; Martinón-Torres F; Nadel S
    Arch Dis Child; 2015 Jun; 100(6):514-6. PubMed ID: 25670403
    [No Abstract]   [Full Text] [Related]  

  • 2. Can we defeat meningococcal disease in low and middle income countries?
    Greenwood B; Chiarot E; MacLennan CA; O'Ryan M
    Vaccine; 2012 May; 30 Suppl 2():B63-6. PubMed ID: 22607901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal B vaccine.
    Murphy JF
    Ir Med J; 2013 Oct; 106(9):260. PubMed ID: 24416844
    [No Abstract]   [Full Text] [Related]  

  • 4. Group B meningococcal vaccine: recommendations for UK use.
    Pollard AJ; Riordan A; Ramsay M
    Lancet; 2014 Mar; 383(9923):1103-4. PubMed ID: 24661533
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Cost-Effectiveness Analyses for Decisions About Vaccination Programs for Meningococcal Disease in the United States, United Kingdom, The Netherlands, and Canada.
    Huang L; Mauskopf J; Farkouh R; Masaquel C
    Expert Rev Vaccines; 2021 Jan; 20(1):59-72. PubMed ID: 33455487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meningococcal vaccine. Editorial].
    Gendrel D; Cohen R
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S47-8. PubMed ID: 22883365
    [No Abstract]   [Full Text] [Related]  

  • 10. MenB (Bexsero) immunisation side effects in extremely premature infants (<28 weeks).
    Mukherjee A; Mukherjee D; Rajai A; Senthil S; Edi-Osagie N
    Arch Dis Child Fetal Neonatal Ed; 2018 Jan; 103(1):F85. PubMed ID: 28942434
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.
    MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW
    MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post licensing evaluation of meningococcal C conjugate vaccine efficacy.
    Commun Dis Rep CDR Wkly; 1999 Oct; 9(40):355. PubMed ID: 10520567
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Bilukha OO; Rosenstein N;
    MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.
    Macneil JR; Cohn AC; Zell ER; Schmink S; Miller E; Clark T; Messonnier NE;
    Pediatr Infect Dis J; 2011 Jun; 30(6):451-5. PubMed ID: 21206392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent meningococcal conjugated vaccine: a routine or selective vaccine in Europe?
    Masuet-Aumatell C; Borrow R; Zuckerman JN
    J Infect; 2012 Sep; 65(3):193-6. PubMed ID: 22543314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.